Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum

Jason S. Griffith, Peter A. Binkley, Namir B. Kirma, Robert S. Schenken, Craig A. Witz, Rajeshwar R. Tekmal

Research output: Contribution to journalArticle

4 Scopus citations


Objective: To characterize imatinib's effect on endometrial stromal cell (ESC) attachment, proliferation, and invasion in modeled peritoneum. Design: In vitro study. Setting: Academic medical center. Patient(s): Twelve normally cycling women. Intervention(s): Imatinib treatment in ESCs from women without endometriosis. Main Outcome Measure(s): Rate of ESC attachment, proliferation, and invasion. Result(s): Imatinib treatment at 10 μM had no effect on ESC attachment. Treatment with 0.5 μM, 2 μM, and 10 μM of imatinib reduced ESC proliferation by 30%, 72%, and 76%, respectively. The 0.1 μM dose of imatinib had no effect on proliferation. Treatment with 5 μM and 10 μM of imatinib reduced ESC invasion by 30% and 73%, respectively. The 2 μM dose had no effect on invasion. Conclusion(s): Imatinib treatment reduces ESC proliferation and invasion in modeled peritoneum without altering attachment. Imatinib may have a therapeutic role in endometriosis treatment.

Original languageEnglish (US)
Pages (from-to)2531-2535
Number of pages5
JournalFertility and Sterility
Issue number7
Publication statusPublished - Dec 1 2010



  • Endometriosis
  • imatinib
  • modeled peritoneum
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this